A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, parallel group study will investigate the
safety and tolerability, and the effect of aleglitazar in combination with ibuprofen on renal
function, renin-angiotensin system and pharmacokinetics in healthy volunteers. Volunteers
will be randomized to receive daily doses of aleglitazar or placebo in combination with
ibuprofen. The anticipated time on study drug is 5 weeks.